21
Aug

Following fast on the heels of a rival development team at Novartis, Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab compared to Pfizer’s Enbrel in a head-to-head study. And Lilly says the results are good enough to back a regulatory filing in the first half of 2015 for its IL-17A therapy as it races to gain some new approvals following a punishing onslaught of generic competition to its top drug franchises.

…read more

Source: Eli Lilly joins list of Enbrel-beaters with head-to-head psoriasis showdown

    

0 No comments